Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: A-HYDROCORT

« Back to Dashboard
A-hydrocort is a drug marketed by Abbott and Hospira and is included in ten NDAs.

The generic ingredient in A-HYDROCORT is hydrocortisone sodium succinate. There are fifty-two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the hydrocortisone sodium succinate profile page.

Summary for Tradename: A-HYDROCORT

Patents:0
Applicants:2
NDAs:10

Clinical Trials for: A-HYDROCORT

The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids in Patients With Corticotropic Hypopituitarism
Status: Recruiting Condition: Hypopituitarism; Hydrocortisone; Lipids; Fatty Acids, Nonesterified; Insulin Sensitivity

Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia
Status: Active, not recruiting Condition: Addison Disease; Adrenal Hyperplasia Congenital

Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
Status: Completed Condition: Congenital Adrenal Hyperplasia; 21-Hydroxylase Deficiency; Adrenogenital Syndrome

Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration
Status: Completed Condition: Major Depressive Disorder; Anxiety Disorders

Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency
Status: Completed Condition: Adrenal Insufficiency

Effect of Slow Release Hydrocortisone on Fed & Fasting Volunteers; Immediate Release on Fasting Only
Status: Completed Condition: Healthy

Pharmacokinetics of Hydrocortisone After Subcutaneous Administration in Chronic Adrenal Insufficiency
Status: Completed Condition: Primary Adrenal Insufficiency

Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism
Status: Enrolling by invitation Condition: Adrenal Insufficiency

An Investigational Study of Hydrocortisone
Status: Completed Condition: Adrenal Insufficiency

Efficacy Study of Low-Dose Hydrocortisone Treatment for Fibromyalgia
Status: Completed Condition: Fibromyalgia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbott
A-HYDROCORT
hydrocortisone sodium succinate
INJECTABLE;INJECTION089580-001Apr 11, 1989DISCNNo<disabled><disabled>
Hospira
A-HYDROCORT
hydrocortisone sodium succinate
INJECTABLE;INJECTION040666-001Apr 6, 2006RXNo<disabled><disabled>
Abbott
A-HYDROCORT
hydrocortisone sodium succinate
INJECTABLE;INJECTION089578-001Apr 11, 1989DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc